Web Desc
Antibodies as Drugs: Immunological Scaffolds as Therapeutics
joint with Tumor Immunology: Multidisciplinary Science Driving Combination Therapy
Organizer(s): Pablo Umaña, Mark X. Sliwkowski and Martin J. Glennie
Date: February 08 - 13, 2015
Location: Fairmont Banff Springs, Banff, AB, Canada
Sponsored by Genentech, Inc., ImmunoGen, Inc., Mersana Therapeutics, OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc. and Shire Human Genetic Therapies
Summary of Meeting:
Monoclonal antibodies are now an established class of drugs in oncology and inflammation. In addition, exciting progress has been recently made on next-generation, engineered therapeutic antibodies and alternative immunological scaffolds, with the first examples from this class being recently approved by the FDA and EMA. This Keystone Symposia meeting will review progress in this area, including lessons learned in the clinic and how this can be applied to new targets and drug candidates. The meeting will cover major areas of activity including: 1) Increasing antibody potency via antibody engineering, better engaging immune effector cells, and improvements in targeted delivery of effectors via fusion proteins and via conjugation of cytotoxic drugs; 2) Applying alternative targeting approaches to increase the therapeutic window, such as pre-targeting and site-specific antibody unmasking; 3) Novel antibodies in areas outside of oncology, including infectious diseases, neurology and chronic inflammation; 4) Engineering antibodies and scaffolds for alternative delivery routes and improved disposition; 5) Clinical progress with multi-specific antibodies; and 6) Recent advances in (i) addressing difficult targets such as GPCRs and ion channels, (ii) alternative immunological scaffolds, and (iii) novel antibody library technologies. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on “Tumor Immunology - Multidisciplinary Science Driving Combination Therapy,” which will be co-located with this meeting.
Scholarship Deadline: October 9 2014
Discounted Abstract Deadline: October 9 2014
Abstract Deadline: November 12 2014
Discounted Registration Deadline: December 9 2014
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Genentech, Inc.ImmunoGen, Inc.Mersana TherapeuticsOncoMed Pharmaceuticals, Inc.Pfizer Inc.Regeneron Pharmaceuticals, Inc.Shire Human Genetic Therapies
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

AbbVie Inc.

Amgen Inc.

BioNTech RNA Pharmaceuticals GmbH

Celldex Therapeutics, Inc.

Genentech, Inc.

Heptares Therapeutics Ltd

Janssen R&D: Pharmaceutical Companies of Johnson & Johnson

MedImmune

Merrimack Pharmaceuticals

Molecular Partners AG

Regeneron Pharmaceuticals, Inc.

Roche Diagnostics GmbH
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI116024-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, February 08 | 4:00PM - 8:00PM
Arrival and Registration
Room: Van Horne Foyer


Sunday, February 08 | 6:00PM - 8:00PM
Welcome Mixer
Room: Van Horne Foyer
No registration fees are used to fund alcohol served at this function.

Monday, February 09 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Monday, February 09 | 8:00AM - 9:00AM
Keynote Address
Room: Van Horne Ballroom C

Speaker 1 of 1
Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
Antibodies Blocking the PD-1 Pathway: A New Age for Cancer Therapy

Monday, February 09 | 9:00AM - 11:30AM
Antibody Drug Conjugates in the Clinic
Room: Van Horne Ballroom C

Speaker 1 of 5
* Peter D. Senter, Seattle Genetics Inc., USA
Potent Antibody-Based Conjugates for Cancer Therapy: From Early-Stage Research to a Clinically Approved Drug

Monday, February 09 | 9:00AM - 11:30AM
Antibody Drug Conjugates in the Clinic
Room: Van Horne Ballroom C

Speaker 2 of 5
William C. Olson, Regeneron Pharmaceuticals, Inc., USA
Clinical-Stage ADCs: What's Trending Amongst this 50ish Crowd

Monday, February 09 | 9:00AM - 11:30AM
Antibody Drug Conjugates in the Clinic
Room: Van Horne Ballroom C

Speaker 3 of 5
Joseph J. Bellucci, Duke University, USA
Short Talk: A Non-Canonical Function of Sortase Enables Conjugation of Small Molecules to Lysine Residues in Proteins

Monday, February 09 | 9:00AM - 11:30AM
Antibody Drug Conjugates in the Clinic
Room: Van Horne Ballroom C

Speaker 4 of 5
Philipp Müller, University Hospital Basel, Switzerland
Short Talk: The Antibody-Drug-Conjugate T-DM1 Induces Potent Anti-Tumor Immunity in HER2+ Breast Cancer: Implications for Combinations with Immunotherapy

Monday, February 09 | 9:00AM - 11:30AM
Antibody Drug Conjugates in the Clinic
Room: Van Horne Ballroom C

Speaker 5 of 5
Sabine Imhof-Jung, Roche Innovation Center Penzberg, Germany
Clinical Progress with Anti-Cancer Cytolytic Fusion Proteins

Monday, February 09 | 9:30AM - 11:45AM
Inflammation and the Dynamics of the Tumor Microenvironment
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 1 of 5
Robert Peter Gale, Hammersmith and Celgene, USA
The Diversity of Myeloid Cell Populations Driving Carcinogenesis


Monday, February 09 | 9:30AM - 11:45AM
Inflammation and the Dynamics of the Tumor Microenvironment
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 2 of 5
Amy-Jo Casbon, Amgen, USA
Short Talk: Tumors Reprogram Early Myeloid Differentiation in the Bone Marrow to Generate Immunosuppressive Neutrophils


Monday, February 09 | 9:30AM - 11:45AM
Inflammation and the Dynamics of the Tumor Microenvironment
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 3 of 5
Guido Kroemer, Cordeliers Research Center, France
How Chemotherapeutics Start an Intratumoral Anticancer Immune Response


Monday, February 09 | 9:30AM - 11:45AM
Inflammation and the Dynamics of the Tumor Microenvironment
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 4 of 5
* Elizabeth M. Jaffee, Johns Hopkins University, USA
Combinatorial Immunotherapies with the Potential to Reverse the Carcinogenesis Process


Monday, February 09 | 9:30AM - 11:45AM
Inflammation and the Dynamics of the Tumor Microenvironment
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 5 of 5
Natasa Obermajer, University of Pittsburgh, USA
Short Talk: Th17 into Treg Cell Conversion: A Novel Pathway of Treg Cell Emergence


Monday, February 09 | 9:40AM - 10:00AM
Coffee Break
Room: Van Horne Foyer


Monday, February 09 | 11:30AM - 1:00PM
Poster Setup
Room: Mezzanine 2


Monday, February 09 | 11:30AM - 2:30PM
On Own for Lunch


Monday, February 09 | 1:00PM - 10:00PM
Poster Viewing
Room: Mezzanine 2


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
Room: Van Horne Ballroom C

Speaker 1 of 8
* Pablo Umaña, Roche Innovation Center Zürich, Switzerland

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
Room: Van Horne Ballroom C

Speaker 2 of 8
* Michael Stumpp, Molecular Partners, Switzerland

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
Room: Van Horne Ballroom C

Speaker 3 of 8
David P. Chimento, Rockland Immunochemicals, Inc., USA
Differential Affinity Single Domain Antibodies: Novel Agents for in vivo Imaging and Targeted Therapies

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
Room: Van Horne Ballroom C

Speaker 4 of 8
Birgit Dreier, University of Zürich, Switzerland
Generic Adenovirus Delivery System Using Bispecific DARPin-Based Adapters

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
Room: Van Horne Ballroom C

Speaker 5 of 8
Kyle Landgraf, AvidBiotics Corp., USA
Engineering Human MICA as a Novel Immunotherapeutic Scaffold

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
Room: Van Horne Ballroom C

Speaker 6 of 8
Tao Dao, Memorial Sloan Kettering, USA
Potent Therapeutic Activity of a TCR-Mimic Bi-Specific T Cell Engager Antibody against Human Cancers Expressing WT1 in the Context of HLA-A02

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
Room: Van Horne Ballroom C

Speaker 7 of 8
Johan Nilvebrant, Royal Institute of Technology, Sweden
ADAPT - A Novel Scaffold Protein for Radionuclide Molecular Imaging

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Novel Scaffolds
Room: Van Horne Ballroom C

Speaker 8 of 8
Sabrina Oliveira, Utrecht University, Netherlands
Nanobody-Photosensitizer Conjugates as an Alternative Format for Targeted Photodynamic Therapy

Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 1 of 9
* Axel Hoos, GlaxoSmithKline, USA


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 2 of 9
* Ira Mellman, Genentech, Inc., USA


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 3 of 9
* Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 4 of 9
* Elizabeth M. Jaffee, Johns Hopkins University, USA


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 5 of 9
Arthur Machlenkin, Pantheon Biosciences Ltd, Israel
Identification of Novel Immuno-Modulatory Targets for Cancer Immunotherapy


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 6 of 9
Bruce Freimark, Pulse Biosciences, USA
Antibody-Mediated Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Affecting Myeloid-Derived Suppressor Cells (MDSC) and Lymphocyte Populations in the Tumor Microenvironment


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 7 of 9
Marit Martha van Buuren, Neon Therapeutics, USA
Intratumoral CD4+ T Cell Reactivity Against Mutated Antigens Is Commonly Observed in Human Melanoma


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 8 of 9
Francisca Wollerton, F-star, UK
Modular Antibody TechnologyTM Platform Delivers Molecules of Diverse Formats and Biology


Monday, February 09 | 2:30PM - 4:30PM
Workshop 1: Integration of Science through Collaboration - N
ew Models
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 9 of 9
Jennie R. Lill, Genentech, Inc., USA
Mass-Spectrometry Based Characterization of the MHC-I Peptide Repertoire in Response to Drug Treatment


Monday, February 09 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Monday, February 09 | 5:00PM - 7:00PM
Antibody-Targeted Fusion Proteins for Cancer Therapy
Room: Van Horne Ballroom C

Speaker 1 of 4
Mark X. Sliwkowski, Genentech, Inc., USA
Antibody Therapeutics in the Treatment of HER2-Positive Cancer: Past, Present and Future

Monday, February 09 | 5:00PM - 7:00PM
Antibody-Targeted Fusion Proteins for Cancer Therapy
Room: Van Horne Ballroom C

Speaker 2 of 4
Sherie L. Morrison, University of California, Los Angeles, USA
Antibody Fusions with Interferon for the Treatment of Malignancy

Monday, February 09 | 5:00PM - 7:00PM
Antibody-Targeted Fusion Proteins for Cancer Therapy
Room: Van Horne Ballroom C

Speaker 3 of 4
* Tibor P. Keler, Celldex Therapeutics, Inc., USA
DC-Targeted Antibody Fusions as Cancer Vaccines

Monday, February 09 | 5:00PM - 7:00PM
Antibody-Targeted Fusion Proteins for Cancer Therapy
Room: Van Horne Ballroom C

Speaker 4 of 4
Christian Klein, Roche, Switzerland
Short Talk: CEA-Targeted IL-2 Variant (IL2v)-Based Immunocytokine for Immunotherapy of Cancer

Monday, February 09 | 5:00PM - 7:15PM
Genetics and Epigenetics of the Immune System
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 1 of 5
Tak W. Mak, Campbell Family Institute for Breast Cancer, Canada
Genetic and Epigenetic Alterations that Drive Neoantigen Development


Monday, February 09 | 5:00PM - 7:15PM
Genetics and Epigenetics of the Immune System
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 2 of 5
Morten Frier Gjerstorff, University of Southern Denmark, Denmark
Short Talk: Oncogenic Functions of Cancer/Testis Antigen SSX2 Highlight its Therapeutic Potential


Monday, February 09 | 5:00PM - 7:15PM
Genetics and Epigenetics of the Immune System
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 3 of 5
* Laurence Zitvogel, Institut Gustave Roussy, France
Gut Microbiota and Anticancer Immune Responses


Monday, February 09 | 5:00PM - 7:15PM
Genetics and Epigenetics of the Immune System
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 4 of 5
Eduardo M. Sotomayor, Moffitt Cancer Center and Research Institute, USA
Combinatorial Approaches that Integrate Epigenetic Therapy with Immunotherapy


Monday, February 09 | 5:00PM - 7:15PM
Genetics and Epigenetics of the Immune System
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 5 of 5
Brian H. Ladle, Johns Hopkins University, USA
Short Talk: De novo DNA Methylation by DNMT3a Controls CD8+ T Cell Fate Decisions following Activation


Monday, February 09 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Monday, February 09 | 7:30PM - 10:00PM
Poster Session 1
Room: Mezzanine 2


Tuesday, February 10 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Tuesday, February 10 | 8:00AM - 11:15AM
Antibodies for Cancer Immunotherapy
Room: Van Horne Ballroom C

Speaker 1 of 6
Alan J. Korman, Vir Biotechnology, Inc., USA
Anti-Tumor Activity of Immunomodulatory Antibodies

Tuesday, February 10 | 8:00AM - 11:15AM
Antibodies for Cancer Immunotherapy
Room: Van Horne Ballroom C

Speaker 2 of 6
* Martin J. Glennie, University of Southampton, UK
Agonistic Antibodies Targeting Costimulatory Receptors

Tuesday, February 10 | 8:00AM - 11:15AM
Antibodies for Cancer Immunotherapy
Room: Van Horne Ballroom C

Speaker 3 of 6
* Pablo Umaña, Roche Innovation Center Zürich, Switzerland
Enhancing Immune Effector Functions: Gazyva and Beyond

Tuesday, February 10 | 8:00AM - 11:15AM
Antibodies for Cancer Immunotherapy
Room: Van Horne Ballroom C

Speaker 4 of 6
Patrick A. Baeuerle, Amgen Research (Munich) GmbH, Germany
Clinical Progress with T Cell-Engaging Bispecific Antibodies

Tuesday, February 10 | 8:00AM - 11:15AM
Antibodies for Cancer Immunotherapy
Room: Van Horne Ballroom C

Speaker 5 of 6
Elizabeth E. Evans, Vaccinex, Inc., USA
Short Talk: Anti-Semaphorin 4D Therapeutic Antibody Recruits Activated Tumor Infiltrating Leukocytes and Reverses Tumor Growth

Tuesday, February 10 | 8:00AM - 11:15AM
Antibodies for Cancer Immunotherapy
Room: Van Horne Ballroom C

Speaker 6 of 6
Rupali Das, Children's Hospital of Philadelphia, USA
Short Talk: Cancer Immunotherapeutic Potential of NKTT320, a Novel Human iNKT Cell Activating Monoclonal Antibody

Tuesday, February 10 | 8:00AM - 11:00AM
Genomic, Metabolomic and Proteomic Advances in Cancer Immuno
therapy
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 1 of 5
* Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
Neo-Antigens in Human Cancer


Tuesday, February 10 | 8:00AM - 11:00AM
Genomic, Metabolomic and Proteomic Advances in Cancer Immuno
therapy
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 2 of 5
Lélia Delamarre, Genentech, Inc., USA
Short Talk: Predictive Identification of Immunogenic Mutations in Cancer


Tuesday, February 10 | 8:00AM - 11:00AM
Genomic, Metabolomic and Proteomic Advances in Cancer Immuno
therapy
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 3 of 5
Matthew M. Gubin, Washington University in St. Louis, USA
Short Talk: Checkpoint Blockade Cancer Therapy Targets Tumor-Specific Mutant Antigens


Tuesday, February 10 | 8:00AM - 11:00AM
Genomic, Metabolomic and Proteomic Advances in Cancer Immuno
therapy
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 4 of 5
Jonathan D. Powell, Johns Hopkins University School of Medicine, USA
Targeting mTOR and Metabolism to Enhance Anti-Tumor Immunotherapy


Tuesday, February 10 | 8:00AM - 11:00AM
Genomic, Metabolomic and Proteomic Advances in Cancer Immuno
therapy
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 5 of 5
Antony Rosen, Johns Hopkins University School of Medicine, USA
Cancer and the Autoimmune Rheumatic Diseases: Mechanistic Insights


Tuesday, February 10 | 9:20AM - 9:40AM
Coffee Break
Room: Van Horne Foyer


Tuesday, February 10 | 11:15AM - 1:00PM
Poster Setup
Room: Mezzanine 2


Tuesday, February 10 | 11:15AM - 5:00PM
On Own for Lunch


Tuesday, February 10 | 1:00PM - 10:00PM
Poster Viewing
Room: Mezzanine 2


Tuesday, February 10 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Tuesday, February 10 | 5:00PM - 7:00PM
Alternative Tumor Targeting Approaches
Room: Van Horne Ballroom C

Speaker 1 of 4
* Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Limits of Tumor Targeting in Immunotherapy: Theory and Experiment

Tuesday, February 10 | 5:00PM - 7:00PM
Alternative Tumor Targeting Approaches
Room: Van Horne Ballroom C

Speaker 2 of 4
Bryan A. Irving, CytomX Therapeutics, Inc, USA
Probodies Empower a New Generation of Antibody Immunotherapies

Tuesday, February 10 | 5:00PM - 7:00PM
Alternative Tumor Targeting Approaches
Room: Van Horne Ballroom C

Speaker 3 of 4
Peter Molloy, Immunocore Ltd., UK
ImmTACs: Bi-specific TCR-based Reagents for Targeted Cancer Immunotherapy

Tuesday, February 10 | 5:00PM - 7:00PM
Alternative Tumor Targeting Approaches
Room: Van Horne Ballroom C

Speaker 4 of 4
Heather A. Huet, Novartis Institutes for Biomedical Research, USA
Short Talk: Targeting Ovarian Cancer with ESK1, a Glycoengineered TCR-Mimic Antibody Directed Against the Intracellular Transcription Factor WT1 with Enhanced ADCC Killing

Tuesday, February 10 | 5:00PM - 7:00PM
Human Immunology: Functional Insights for Cancer Immunothera
py
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 1 of 4
Eliane Piaggio, INSERM Immunity and Cancer - Institut Curie, France
Short Talk: Lymph Node Invasion by Tumor Cells Modifies the Distribution and Phenotype of Dendritic and T Cell Subsets in Breast Cancer Patients


Tuesday, February 10 | 5:00PM - 7:00PM
Human Immunology: Functional Insights for Cancer Immunothera
py
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 2 of 4
* Pia Kvistborg, Netherlands Cancer Institute, Netherlands
Effects of Checkpoint Targeting on the Tumor-Specific T Cell Response


Tuesday, February 10 | 5:00PM - 7:00PM
Human Immunology: Functional Insights for Cancer Immunothera
py
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 3 of 4
Steven M. Larson, Memorial Sloan-Kettering Cancer Center, USA
Radioimmunotherapy (RIT) of Solid Tumors


Tuesday, February 10 | 5:00PM - 7:00PM
Human Immunology: Functional Insights for Cancer Immunothera
py
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 4 of 4
Jay A. Berzofsky, NCI, National Institutes of Health, USA
Talk Title to be Announced


Tuesday, February 10 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Tuesday, February 10 | 7:30PM - 10:00PM
Poster Session 2
Room: Mezzanine 2


Wednesday, February 11 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de

Room: Van Horne Ballroom C

Speaker 1 of 7
* Mark X. Sliwkowski, Genentech, Inc., USA

Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de

Room: Van Horne Ballroom C

Speaker 2 of 7
Gabriele Schaefer, Genentech, Inc., USA
MEHD7495A, a Dual-Action-Antibody Targeting HER3 and EGFR: Preclinical and Clinical Evaluation

Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de

Room: Van Horne Ballroom C

Speaker 3 of 7
Alexey Lugovskoy, Merrimack Pharmaceuticals Inc., USA
MM-141: Dual Antibody Inhibitor of IGF-1R and ErbB3 Targeting Redundancies and Adaptation in Oncogenic Signaling

Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de

Room: Van Horne Ballroom C

Speaker 4 of 7
Oliver Krieter, Germany
Clinical Progress with RG7221 (RO5520985), a Bi-Specific Human IgG1 Antibody Against Ang-2 and VEGF-A for the Treatment of Cancer

Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de

Room: Van Horne Ballroom C

Speaker 5 of 7
Tariq Ghayur, AbbVie, Inc., USA
Preclinical and Clinical Progress of Dual-Variable-Domain-Ig (DVD-IgTM) Molecules for Autoimmune Indications

Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de

Room: Van Horne Ballroom C

Speaker 6 of 7
Mathias Locher, Covagen AG, Switzerland
Short Talk: COVA322: A Clinical Stage TNF/IL-17A Bispecific FynomAb for the Treatment of Inflammatory Diseases

Wednesday, February 11 | 8:00AM - 11:15AM
Clinical Progress with Bispecific Antibodies for Dual Blocka
de

Room: Van Horne Ballroom C

Speaker 7 of 7
Miho Funaki, Chugai Pharmaceutical Co. Ltd., Japan
Short Talk: Novel Bispecific Antibody against Activated Factor IXa and Factor X (ACE910) for Treatment of Hemophilia A

Wednesday, February 11 | 8:00AM - 11:00AM
Influence of Conventional Therapies on the Immune System
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 1 of 5
Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Immune Responses to Immune Checkpoint Therapies


Wednesday, February 11 | 8:00AM - 11:00AM
Influence of Conventional Therapies on the Immune System
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 2 of 5
* Ira Mellman, Genentech, Inc., USA
Targeted Molecular Therapy Takes on Immunotherapy


Wednesday, February 11 | 8:00AM - 11:00AM
Influence of Conventional Therapies on the Immune System
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 3 of 5
Dan G. Duda, Harvard Medical School, Massachusetts General Hospital, USA
Short Talk: Rationally Combining Antiangiogenic Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma


Wednesday, February 11 | 8:00AM - 11:00AM
Influence of Conventional Therapies on the Immune System
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 4 of 5
Daniel E. Speiser, Ludwig Center, University of Lausanne, Switzerland
Multidisciplinary Approaches to Target both Cancer Cell-Internal and -External Disease Mechanisms


Wednesday, February 11 | 8:00AM - 11:00AM
Influence of Conventional Therapies on the Immune System
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 5 of 5
Roopa Srinivasan, GlaxoSmithKline, USA
Effects of Targeted Therapies on Tumor and Immune System


Wednesday, February 11 | 9:20AM - 9:40AM
Coffee Break
Room: Van Horne Foyer


Wednesday, February 11 | 11:15AM - 1:00PM
Poster Setup
Room: Mezzanine 2


Wednesday, February 11 | 11:15AM - 5:00PM
On Own for Lunch


Wednesday, February 11 | 1:00PM - 10:00PM
Poster Viewing
Room: Mezzanine 2


Wednesday, February 11 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Wednesday, February 11 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
Room: Van Horne Ballroom C

Speaker 1 of 4
Gerald B. Pier, Harvard Medical School, USA
Anti-Microbial Antibody Therapy

Wednesday, February 11 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
Room: Van Horne Ballroom C

Speaker 2 of 4
* Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Broadly Neutralizing Anti-Viral Antibodies

Wednesday, February 11 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
Room: Van Horne Ballroom C

Speaker 3 of 4
Yaoxing Huang, Aaron Diamond AIDS Research Center (ADARC), USA
Passive Immunization Approaches to HIV Prevention

Wednesday, February 11 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
Room: Van Horne Ballroom C

Speaker 4 of 4
Ian Huh, California State University, Fresno, USA
Short Talk: Neutralization of Listeria monocytogenes by Single Domain Antibodies

Wednesday, February 11 | 5:00PM - 7:15PM
Advances in Therapeutic Platforms: Vaccines, Cellular Therap
ies and Immune Modulators
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 1 of 5
Laurence J. N. Cooper, ZIOPHARM Oncology, Inc., USA
Genetic Modification of T Cells Using Sleeping Beauty System for Human Applications


Wednesday, February 11 | 5:00PM - 7:15PM
Advances in Therapeutic Platforms: Vaccines, Cellular Therap
ies and Immune Modulators
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 2 of 5
* Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Synergy of Therapeutic Vaccination Against HPV16 Oncogenic Proteins and Conventional Chemotherapeutics


Wednesday, February 11 | 5:00PM - 7:15PM
Advances in Therapeutic Platforms: Vaccines, Cellular Therap
ies and Immune Modulators
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 3 of 5
Khaled H. Barakat, University of Alberta, Canada
Short Talk: Rational Design of Small Molecule Immune Checkpoints' Inhibitors


Wednesday, February 11 | 5:00PM - 7:15PM
Advances in Therapeutic Platforms: Vaccines, Cellular Therap
ies and Immune Modulators
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 4 of 5
Jolanda de Vries, NCMLS, Radboud University Medical Center, Netherlands
Natural Dendritic Cell Vaccine: A More Powerful Next Generation?


Wednesday, February 11 | 5:00PM - 7:15PM
Advances in Therapeutic Platforms: Vaccines, Cellular Therap
ies and Immune Modulators
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 5 of 5
Sandeep T. Koshy, Harvard University, USA
Short Talk: Tumor Immunomodulation Using an Injectable Biomaterials Scaffold


Wednesday, February 11 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Wednesday, February 11 | 7:30PM - 10:00PM
Poster Session 3
Room: Mezzanine 2


Thursday, February 12 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Thursday, February 12 | 8:00AM - 11:15AM
Engineering Immunological Scaffolds for Improved Delivery an
d Disposition

Room: Van Horne Ballroom C

Speaker 1 of 6
* Serge Muyldermans, Vrije Universiteit Brussel, Belgium
Nanobodies for Alternative Delivery Routes

Thursday, February 12 | 8:00AM - 11:15AM
Engineering Immunological Scaffolds for Improved Delivery an
d Disposition

Room: Van Horne Ballroom C

Speaker 2 of 6
Kristen M. Picha, Centyrex, Janssen Research & Development, USA
Novel Delivery Strategies for Alternative Scaffolds

Thursday, February 12 | 8:00AM - 11:15AM
Engineering Immunological Scaffolds for Improved Delivery an
d Disposition

Room: Van Horne Ballroom C

Speaker 3 of 6
Tomoyuki Igawa, Chugai Pharmabody Research, Singapore
Engineered pH-Dependent Binding Antibody for Efficient Elimination of Soluble Antigen from Plasma

Thursday, February 12 | 8:00AM - 11:15AM
Engineering Immunological Scaffolds for Improved Delivery an
d Disposition

Room: Van Horne Ballroom C

Speaker 4 of 6
* Michael Stumpp, Molecular Partners, Switzerland
DARPins for Ocular Diseases and Beyond

Thursday, February 12 | 8:00AM - 11:15AM
Engineering Immunological Scaffolds for Improved Delivery an
d Disposition

Room: Van Horne Ballroom C

Speaker 5 of 6
Yu-Ju Gloria Meng, Genentech, Inc., USA
Short Talk: Intravitreally Injected Bispecific F(ab’)2 Had Similar Intraocular Concentrations and Reduced Circulating Concentrations Compared to IgG

Thursday, February 12 | 8:00AM - 11:15AM
Engineering Immunological Scaffolds for Improved Delivery an
d Disposition

Room: Van Horne Ballroom C

Speaker 6 of 6
Jens Niewoehner, Roche Pharma Research and Early Development, Germany
Short Talk: Engineering a Brain Shuttle for Therapeutic Protein Delivery

Thursday, February 12 | 8:00AM - 11:00AM
Methodological Advances in Clinical and Biomarker Investigat
ion
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 1 of 4
Ugur Sahin, BioNTech AG, Germany
Individualized Cancer Immunotherapy


Thursday, February 12 | 8:00AM - 11:00AM
Methodological Advances in Clinical and Biomarker Investigat
ion
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 2 of 4
James P. Allison, University of Texas MD Anderson Cancer Center, USA
Investigating Emerging Checkpoint Targets and their Modulators


Thursday, February 12 | 8:00AM - 11:00AM
Methodological Advances in Clinical and Biomarker Investigat
ion
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 3 of 4
Taha Merghoub, Memorial Sloan-Kettering Cancer Center, USA
Genetic Basis Underlying Clinical Response to Checkpoint Blockade


Thursday, February 12 | 8:00AM - 11:00AM
Methodological Advances in Clinical and Biomarker Investigat
ion
This session is from Tumor Immunology

Room: Van Horne Ballroom A/B

Speaker 4 of 4
Nir Hacohen, Massachusetts General Hospital, USA
Genetic and Genomic Analysis of Tumor Immunity


Thursday, February 12 | 9:20AM - 9:40AM
Coffee Break
Room: Van Horne Foyer


Thursday, February 12 | 11:15AM - 2:30PM
On Own for Lunch


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
Room: Van Horne Ballroom C

Speaker 1 of 8
* Pablo Umaña, Roche Innovation Center Zürich, Switzerland

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
Room: Van Horne Ballroom C

Speaker 2 of 8
* Catherine Hutchings, Heptares Therapeutics, UK

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
Room: Van Horne Ballroom C

Speaker 3 of 8
Belay Gessesse Bezabeh, University of Tokyo, Japan
Cell-Free Synthesis of the Human Chemokine G-Protein Coupled Receptor for Future Antibody Screening

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
Room: Van Horne Ballroom C

Speaker 4 of 8
Ling Chen, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, China
Rapid Generation of Antiviral Antibodies for Human Application in Rhesus macaques in Responding to Emerging Influenza and Virulent Viral Infections

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
Room: Van Horne Ballroom C

Speaker 5 of 8
Amandeep K. Gakhal, Sutro Biopharma, USA
Discovery and Characterization of Therapeutic Antibodies for an Engineered Cell-Free Expression System

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
Room: Van Horne Ballroom C

Speaker 6 of 8
Ben Hoffstrom, Fred Hutchinson Cancer Research Center, USA
High-Throughput Screening for Monoclonal Antibodies to Multiplexed Antigens

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
Room: Van Horne Ballroom C

Speaker 7 of 8
Michael-Paul Robinson, Cornell University, USA
Production of Full-length Antibodies in the Cytoplasm of E. coli

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: New Library Design and Screening Technologies
Room: Van Horne Ballroom C

Speaker 8 of 8
Imre Kacskovics, ImmunoGenes Ltd, Hungary
Transgenic Animals that Overexpress the Neonatal Fc Receptor (FcRn) Have Improved Antibody Generation

Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 1 of 8
* Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 2 of 8
* James P. Allison, University of Texas MD Anderson Cancer Center, USA


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 3 of 8
Jason R. Baird, Earle A. Chiles Research Institute, USA
Radiation Therapy Combined with Novel Oligonucleotides Targeting STING in Tumor Stroma Result in Cure of Established Tumors


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 4 of 8
Hélène Salmon, Institut Curie and Mount Sinai School of Medicine, France
In situ Activation and Expansion of CD103+ DCs at the Tumor Site Dramatically Increase Melanoma Response to BRAF and PDL1 Inhibition Therapy


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 5 of 8
Katherine E. Lewis, Bristol-Myers Squibb Company, USA
Dual Targeting of PD-1 and LAG-3 Demonstrates Superior Efficacy to Blocking Either PD-1 or LAG-3 Alone in Pre-Clinical Solid and Hematological Tumor Models


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 6 of 8
Carola H. Ries, Roche Innovation Center Munich, Germany
Targeting Tumor-Associated Macrophages with Anti-CSF1R Antibody in Combination with Chemotherapy


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 7 of 8
Ryan Rountree, Nurix, Inc., USA
Poxvirus-Based Active Immunotherapy Induces PD-L1 Expression in the Tumor Microenvironment and Results in Dramatic Anti-Tumor Efficacy in Combination with PD-1 Axis Blockade


Thursday, February 12 | 2:30PM - 4:30PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunother
apy - Lessons from Failures to Enable Future Successes
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 8 of 8
Peter R. Rhode, Altor BioScience Corp., USA
Enhanced Efficacy of Immune Checkpoint Blockers and Therapeutic Antibodies in Combination with an IL-15-Based Superagonist Complex in Various Mouse Tumor Models


Thursday, February 12 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Thursday, February 12 | 5:00PM - 6:45PM
Addressing Difficult Targets - GPCRs and Ion Channels
Room: Van Horne Ballroom C

Speaker 1 of 3
* Catherine Hutchings, Heptares Therapeutics, UK
Using Stabilized Receptors as Antigens to Generate Therapeutic Antibodies to GPCR Targets

Thursday, February 12 | 5:00PM - 6:45PM
Addressing Difficult Targets - GPCRs and Ion Channels
Room: Van Horne Ballroom C

Speaker 2 of 3
Vaughn V. Smider, The Scripps Research Institute, USA
Ultralong CDR3s for Targeting Ion Channels and GPCRs

Thursday, February 12 | 5:00PM - 6:45PM
Addressing Difficult Targets - GPCRs and Ion Channels
Room: Van Horne Ballroom C

Speaker 3 of 3
Caroline Colley, MedImmune, UK
Identifying Antibodies to GPCRs and Ion-Channels

Thursday, February 12 | 5:00PM - 6:45PM
Scientific and Clinical Progress in Combination Therapy
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 1 of 4
* Axel Hoos, GlaxoSmithKline, USA


Thursday, February 12 | 5:00PM - 6:45PM
Scientific and Clinical Progress in Combination Therapy
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 2 of 4
F. Stephen Hodi, Dana-Farber Cancer Institute, USA
Immunological Scaffolds as Therapeutics: A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients


Thursday, February 12 | 5:00PM - 6:45PM
Scientific and Clinical Progress in Combination Therapy
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 3 of 4
Cassian Yee, University of Texas MD Anderson Cancer Center, USA
Adoptive T Cell Therapy: A Personalized Approach for Common Cancers


Thursday, February 12 | 5:00PM - 6:45PM
Scientific and Clinical Progress in Combination Therapy
This session is from Tumor Immunology
Room: Van Horne Ballroom A/B

Speaker 4 of 4
Silvia C. Formenti, New York University Langone Medical Center, USA
Combination Therapy Potential of Radiation Therapy as in-situ Vaccination


Thursday, February 12 | 6:45PM - 7:15PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Van Horne Ballroom C


Thursday, February 12 | 6:45PM - 7:15PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
This session is from Tumor Immunology
Room: Ballroom A/B


Thursday, February 12 | 7:15PM - 8:15PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Thursday, February 12 | 8:00PM - 11:00PM
Entertainment
Room: Mezzanine 2
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, February 12 | 8:00PM - 11:00PM
Cash Bar
Room: Mezzanine 2


Friday, February 13 | 10:25AM - 10:25AM
Departure


*Session Chair.